6826.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 03:53):

Stats
Today's Volume	192 000
Average Volume	139 066
Market Cap	15.30B
EPS	HKD0 ( 2023-10-25 )
Last Dividend	HKD0.441 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	14.05
ATR14	HKD0.0780 (0.21%)

Volume Correlation

Long: 0.29 (neutral)

Short: 0.98 (very strong)

Signal:(40.552) Expect same movement, but be aware

Shanghai Haohai Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Haohai Correlation - Currency/Commodity

-0.32
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.56
( weak negative )

0.51
( weak )

0.36
( neutral )

Shanghai Haohai Financials

Annual	2022
Revenue:	HKD2.10B
Gross Profit:	HKD1.45B (68.79 %)
EPS:	HKD1.040

Q3	2023
Revenue:	HKD676.08M
Gross Profit:	HKD493.48M (72.99 %)
EPS:	HKD0.710

Q2	2023
Revenue:	HKD652.85M
Gross Profit:	HKD463.21M (70.95 %)
EPS:	HKD0.600

Q1	2023
Revenue:	HKD652.85M
Gross Profit:	HKD463.21M (70.95 %)
EPS:	HKD0.600

Financial Reports:

No articles found.

Shanghai Haohai Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.820 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.441 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Shanghai Haohai Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.57 - Stable (31.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.472	2016-06-08
Last Dividend	HKD0.441	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD4.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.28	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.57
Div. Directional Score	8.99	--

Next Divdend (Est)
(2024-07-12)

HKD0.326 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.28

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3990.HK	Ex Dividend Junior	2023-05-25	Annually	0.00%
1809.HK	Ex Dividend Junior	2023-05-24	Annually	0.00%
0838.HK	Ex Dividend Knight	2023-09-07	Annually	0.00%
0004.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
2386.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
1375.HK	Ex Dividend Junior	2023-06-09	Annually	0.00%
0436.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
6811.HK	Ex Dividend Knight	2023-10-05	Semi-Annually	0.00%
1921.HK	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
0954.HK	Ex Dividend Junior	2023-05-22	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.138	1.500	7.24	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0487	1.200	8.38	10.00	[0 - 0.3]
returnOnEquityTTM	0.0610	1.500	-0.433	-0.649	[0.1 - 1]
payoutRatioTTM	0.234	-1.000	7.66	-7.66	[0 - 1]
currentRatioTTM	6.41	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.58	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0388	-1.500	9.35	-10.00	[0 - 0.6]
interestCoverageTTM	65.05	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.59	2.00	9.14	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.581	2.00	9.71	10.00	[0 - 20]
debtEquityRatioTTM	0.0482	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.702	1.000	1.625	1.625	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.12	9.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.607	1.000	2.18	2.18	[0.2 - 2]
assetTurnoverTTM	0.353	0.800	-0.980	-0.784	[0.5 - 2]
Total Score				11.42

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.83	1.000	8.30	0	[1 - 100]
returnOnEquityTTM	0.0610	2.50	-0.278	-0.649	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.581	2.00	9.81	10.00	[0 - 30]
dividendYielPercentageTTM	1.223	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.59	2.00	9.14	10.00	[0 - 30]
payoutRatioTTM	0.234	1.500	7.66	-7.66	[0 - 1]
pegRatioTTM	0.895	1.500	7.37	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.177	1.000	8.09	0	[0.1 - 0.5]
Total Score				6.57

Shanghai Haohai

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.